Custom Cast Podcast

Precision in Practice: Examining the Complexities of Diagnosing Lennox-Gastaut Syndrome

For the full US Prescribing Information, click here. [https://www.epidiolex.com/PI?_gl=1*1a9ql0o*_gcl_au*NjA3MzM1ODg1LjE3NjQxMTUxOTA.] For patients with hard-to-treat epilepsies, a syndrome-specific diagnosis is crucial to ensuring they receive the best possible care, including access to antiseizure medications (ASMs). But some epilepsies evolve and seem more elusive as patients reach adolescence or adulthood. In this final episode of the podcast series, epilepsy experts David Burdette, MD, and Ann Hyslop Segeren, MD, examine how a clear, clinical diagnosis can facilitate appropriate treatment regimens for pediatric and adult patients. They review consensus recommendations for identifying symptoms, navigating historical data, and utilizing resources developed by experts for use by healthcare providers in any diagnostic setting. The basis of this series is a publication in the journal Epilepsia Open. This podcast is sponsored by Jazz Pharmaceuticals and is for US prescribers only. It is intended for informational purposes only and is not a substitute for clinical knowledge or professional judgment. Never disregard professional medical advice or delay in seeking it because of something you have read or heard on this podcast. Podcast presenters are paid consultants for Jazz Pharmaceuticals. There are no certified continued medical education credits approved for the podcast. ©2026 Jazz Pharmaceuticals plc or its subsidiaries. All rights reserved. US-EPX-2500227

Precision in Practice: Navigating Concomitant Therapies for Treatment-Resistant Epilepsy

For the full US Prescribing Information, click here. [https://www.epidiolex.com/PI?_gl=1*1a9ql0o*_gcl_au*NjA3MzM1ODg1LjE3NjQxMTUxOTA.] For individuals living with hard-to-treat epilepsy, patients may be on multiple medications to help manage their seizures. In this episode, epilepsy experts Ann Hyslop Segeren, MD, and David Burdette, MD, continue their conversation about an antiseizure medication (ASM) for the management of seizures associated with treatment-resistant epilepsy. They discuss consensus-driven practices for concomitant use with other ASMs, including how and when to monitor for adverse events, and what to consider when tailoring doses while initiating concomitant treatments. The basis of this series is a publication in the journal Epilepsia Open. This podcast is sponsored by Jazz Pharmaceuticals and is for US prescribers only. It is intended for informational purposes only and is not a substitute for clinical knowledge or professional judgment. Never disregard professional medical advice or delay in seeking it because of something you have read or heard on this podcast. Podcast presenters are paid consultants for Jazz Pharmaceuticals. There are no certified continued medical education credits approved for the podcast. ©2026 Jazz Pharmaceuticals plc or its subsidiaries. All rights reserved. US-EPX-2500226

Precision in Practice: Personalized Therapeutic Approaches to Treatment-Resistant Epilepsy

For the full US Prescribing Information, click here. [https://www.epidiolex.com/PI?_gl=1*1a9ql0o*_gcl_au*NjA3MzM1ODg1LjE3NjQxMTUxOTA.] When it comes to managing seizures associated with hard-to-treat epilepsy, no two patients are the same. Join epilepsy experts David Burdette, MD, and Ann Hyslop Segeren, MD, as they discuss optimizing antiseizure medication (ASM) for patients living with treatment-resistant epilepsy. In this episode, our presenters will provide consensus-based and experience-driven insights into personalized dosing and titration, as well as managing adverse events when initiating an ASM, including balancing efficacy with tolerability. The basis of this series is a publication in the journal Epilepsia Open. This podcast is sponsored by Jazz Pharmaceuticals and is for US prescribers only. It is intended for informational purposes only and is not a substitute for clinical knowledge or professional judgment. Never disregard professional medical advice or delay in seeking it because of something you have read or heard on this podcast. Podcast presenters are paid consultants for Jazz Pharmaceuticals. There are no certified continued medical education credits approved for the podcast. ©2026 Jazz Pharmaceuticals plc or its subsidiaries. All rights reserved. US-EPX-2500225